Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry.
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets under management.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Mar 17, 2022
Deepcell
|
Series B | $73M | Artificial Intelligence | — |
Nov 29, 2021
Lunit
|
Series Unknown | $61M | Artificial Intelligence | — |
Oct 7, 2021
Science 37
|
Post-IPO Equity | $200M | Biotechnology | — |
Sep 1, 2021
SomaLogic
|
Post-IPO Equity | $375M | Biotechnology | — |
Jul 20, 2021
TMRW Life Sciences
|
Series C | $105M | Biotechnology | — |